HIV Vaccine Trial in Thai Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

16,402

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

June 30, 2009

Conditions
HIV Infection
Interventions
BIOLOGICAL

ALVAC-HIV vCP1521 + AIDSVAX

Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL

OTHER

ALVAC Placebo + AIDSVAX Placebo

ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection

Trial Locations (8)

20160

Phan Tong District Hospital, Phan Tong District

20180

Sattahip District Hospital, Sattahip District

20230

Ao Udom Hospital, Sri Racha District

21000

Provincial Health Office, Muang District

Unknown

Ban Lamung District Hospital, Ban Lamung District

Ban Chang District Hospital, Ban Chang District

Ban Khai District Hospital, Ban Khai District

Klaeng District Hospital, Klaeng District

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

United States Army Medical Materiel Development Activity

FED

collaborator

Armed Forces Research Institute of Medical Sciences, Thailand

OTHER_GOV

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

MCM Vaccines B.V.

INDUSTRY

collaborator

VaxGen

INDUSTRY

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

Ministry of Health, Thailand

OTHER_GOV

collaborator

Mahidol University

OTHER

collaborator

Royal Thai Army Medical Department

OTHER_GOV

collaborator

Tripler Army Medical Center

FED

collaborator

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

lead

U.S. Army Medical Research and Development Command

FED

NCT00223080 - HIV Vaccine Trial in Thai Adults | Biotech Hunter | Biotech Hunter